Does TOFACITINIB Cause Product use in unapproved indication? 2,866 Reports in FDA Database
Grow Your Own Natural Pharmacy at Home
Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.
According to the FDA Adverse Event Reporting System (FAERS), 2,866 reports of Product use in unapproved indication have been filed in association with TOFACITINIB (XELJANZ XR). This represents 1.8% of all adverse event reports for TOFACITINIB.
2,866
Reports of Product use in unapproved indication with TOFACITINIB
1.8%
of all TOFACITINIB reports
1,031
Deaths
1,257
Hospitalizations
How Dangerous Is Product use in unapproved indication From TOFACITINIB?
Of the 2,866 reports, 1,031 (36.0%) resulted in death, 1,257 (43.9%) required hospitalization, and 1,209 (42.2%) were considered life-threatening.
Is Product use in unapproved indication Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TOFACITINIB. However, 2,866 reports have been filed with the FAERS database.
What Other Side Effects Does TOFACITINIB Cause?
Drug ineffective (30,382)
Pain (21,659)
Condition aggravated (16,925)
Arthralgia (15,640)
Fatigue (13,551)
Rheumatoid arthritis (12,277)
Off label use (11,736)
Headache (11,061)
Joint swelling (10,686)
Malaise (9,040)
What Other Drugs Cause Product use in unapproved indication?
DUPILUMAB (33,452)
DICLOFENAC (12,197)
METHOTREXATE (8,930)
PREDNISONE (7,625)
RITUXIMAB (7,519)
MYCOPHENOLATE MOFETIL (5,910)
ACETAMINOPHEN (5,819)
CYCLOPHOSPHAMIDE (5,750)
RISPERIDONE (5,551)
TACROLIMUS (5,057)
Which TOFACITINIB Alternatives Have Lower Product use in unapproved indication Risk?
TOFACITINIB vs TOFERSEN
TOFACITINIB vs TOLNAFTATE
TOFACITINIB vs TOLODODEKIN ALFA
TOFACITINIB vs TOLTERODINE
TOFACITINIB vs TOLVAPTAN